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One sentence summary: In the search for novel topical skin therapies, we have examined skin-derived bacteriocins, produced by microbes which have
evolved in such a way as to outcompete pathogens, and successfully colonise the skin environment.
Editor: Julian Marchesi
ABSTRACT
The demand for novel antimicrobial therapies due to the threat posed by antimicrobial resistance has resulted in a growing
interest in the protective role of our skin bacteria and the importance of competition among bacteria on the skin. A survey
of the cultivable bacteria on human skin was undertaken to identify the capacity of the skin microbiota to produce
bacteriocins with activity against skin pathogens. Twenty-one bacteriocins produced by bacteria isolated from seven sites
on the human body of each subject exhibited inhibition spectra ranging from broad to narrow range, inhibiting many
Gram-positive bacteria, including opportunistic skin pathogens such as Propionibacterium acnes (recently renamed
Cutibacterium acnes), Staphylococcus epidermidis and methicillin-resistant Staphylococcus aureus (MRSA). Sequencing indicated
that the antimicrobial-producing isolates were predominately species/strains of the Staphylococcus genus. Colony mass
spectrometry revealed peptide masses that do not correspond to known bacteriocins. In an era where antibiotic resistance
is of major concern, the inhibitory effect of novel bacteriocins from the bacteria of skin origin demonstrates the
antimicrobial potential that could be harnessed from within the human skin microbiota.
Keywords: skin pathogens; staphylococci; antimicrobial potential; bacteriocin; skin microbiota; skin microbiome
INTRODUCTION
The human skin microbiome is home to hundreds of diverse
bacterial species from the four phyla Actinobacteria, Proteobac-
teria, Firmicutes and Bacteriodetes, which act as a part of the
body’s first line of defence against the external environment
(Natsuga 2014). The commensal microbiota of the skin con-
tributes to host health and is thought to play a role in pro-
tecting the host against a wide range of infections. One such
defence mechanism is the production of bacteriocins. Bacte-
riocins are ribsosomally synthesised, heat-stable antimicrobial
peptides that are produced by bacteria that can exhibit both
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broad and narrow range inhibition spectra. Lantibiotics belong
to class I bacteriocins, which are heavily post-translationally
modified—characterised by the presence of lanthionine/B-
methyllanthionine residues (McAuliffe, Ross and Hill 2001). Bac-
teriocins may exert a diverse array of functions from colonising
peptides, which help the producer to become established in a
niche, to killing peptides for eliminating competitors or as sig-
nalling peptides through interactions with other bacteria and
the immune system (Schauber and Gallo 2008; Bastos et al. 2009;
Dobson et al. 2012). The importance of these traits can be seen
where imbalances in the ratio or composition of skinmicrobiota
have been linked to skin diseases/infections such as psoriasis,
atopic dermatitis, acne and impetigo (Yamasaki and Gallo 2008;
Otto 2009; Zeeuwen et al. 2013; Grice 2014). It has been hypoth-
esised that restoration of this natural microbial balance could
potentially alleviate or prevent such skin infections and would
reduce the use of antibiotics to treat these conditions (Sanford
and Gallo 2013).
Staphylococcus species are the dominant bacterial colonisers
of the skin and are divided into two main groups on the basis
of coagulase activity. Coagulase triggers the coagulation of sol-
uble fibrinogen-forming insoluble fibrin, resulting in the forma-
tion of a clot. Thus, coagulase-positive staphylococci, for exam-
ple Staphylococcus aureus, which can reside on the skin surface
as a commensal organism, are potentially pathogenic and are
capable of producing haemolysins and a range of heat-stable
toxins. Conversely, the skin is also colonised by a diverse array
of coagulase-negative Staphylococcus species, which form a part
of the normal commensal bacteria of the skin. The produc-
tion of lantibiotics is abundant within commensal coagulase-
negative staphylococci; for example S. gallinarum, S. epidermidis
and S. hominis produce the lantibiotics gallidermin, epidermin
and hominicin, respectively (Go¨tz et al. 2014). Studies have char-
acterised the human skin microbiome in healthy and diseased
states (Grice and Segre 2011), and while little has been done
in screening the human skin specifically for novel bacteriocins,
there is increasing interest in the human skin microbiome as
a source of competitive strains and novel antimicrobials. This
has led to the discovery of a novel antibiotic, lugdunin, isolated
from a nasal strain of Staphylococcus lugdunensis (Zipperer et al.
2016). Furthermore, the application of human skin commensals
as sources of protection against S. aureus and skin neoplasms
(Nakatsuji et al., 2017, 2018) highlight the potential of human
skin commensals as possible alternative solutions to antibiotics.
Here, we describe one approach targeted specifically at the
isolation of coagulase-negative staphylococcal skin isolates and
investigate their inhibitory activity against a range of skin
pathogens associated with skin infections such as MRSA, atopic
dermatitis and Acne vulgaricus, as well as the causative agents of
mastitis.
MATERIALS AND METHODS
Isolation of antimicrobial-producing skin isolates
Twenty healthy volunteers, 18–65 years of age, 13 females and 7
males, were recruited for this study, which was approved by the
Cork Clinical Research Ethics Committee under Protocol num-
ber APC071. Seven different areas of the body were swabbed,
specifically the retro auricular crease (behind ear), the axil-
lary vault (underarm), the inguinal crease (groin), the umbili-
cus (belly button), the gluteal crease (between lower back and
buttocks), the alar crease (side of nose) and the toe web space
(between toes). Each swab (Amies, PS, Viscose swabs; Sarstedt,
Sinnottstown Lane, Drinagh, Wexford, Ireland) was dipped in
sterile saline before swabbing the body area (Landers, Hoet and
Wittum 2010) and swabs were stored for no more than 12 hr at
4◦C before being homogenised in 2 mL of Maximum Recovery
Diluent (MRD; Oxoid Ltd., Basingstoke, Hampshire, UK). Tenfold
serial dilutionswere performed inMRD and 100μL aliquotswere
spread-plated onto Mannitol Salt Agar (MSA; Oxoid Ltd.) and
Brain Heart Infusion (BHI) agar (Merck, Darmstadt, Germany).All
plates were incubated aerobically at 37◦C for 48 hr. After incuba-
tion, colonies were counted and colonies of different morpholo-
gies and colours were streaked for purity and grown aerobically
in 10 mL of BHI broth (Merck) at 37◦C in a shaking incubator
(311DS Labnet) overnight.
Detection of antimicrobial activity
Spot bioassays for antimicrobial production were then carried
out on the isolates by spotting 10μL of the overnight culture onto
BHI agar; the plates were incubated overnight at 37◦C and then
overlaid with MRS sloppy Lactobacillus MRS broth (BDTM DifcoTM
Trafalgar Scientific Ltd, Leicester, United Kingdom) containing
0.75% agar seeded with 0.25% of an overnight culture of Lacto-
bacillus delbrueckii ssp. bulgaricus LMG 6901 and grown anaero-
bically overnight (see Table 1 for optimal growth conditions of
bacterial strains used in this study). The remaining colonies on
the BHI plates were also overlaid with L. delbrueckii ssp. bulgari-
cus LMG 6901. The MSA plates were overlaid with sloppy (0.75%)
BHI agar seeded with an overnight inoculum of either 0.25% Lis-
teria innocua DPC 3572 or 0.25% MRSA DPC 5645. Colonies from
spot assays and plate overlays that exhibited zones of inhibition
were then inoculated into BHI broth, grown overnight at 37◦C
and stocked in 20% glycerol at −80◦C for further characterisa-
tion (Fig. 1).
Characterisation of antimicrobial activity of skin
isolates
Well diffusion assays (WDA)
Cell-free supernatants (CFS) were prepared from 10 mL
overnight cultures of putative antimicrobial-producing strains
(isolated from BHI and MSA plates) by centrifugation (Sorvall
Legend RT) at 4000 × g for 20 min following overnight growth
in BHI broth in a shaking incubator at 37◦C (Ryan et al. 1996).
To eliminate inhibition due to acids, the CFS were neutralised
to pH 6.9–7.2 using 1 M NaOH. Wells were bored in MRS agar
plates, previously seeded with 0.25% inoculum of an overnight
culture of L. delbrueckii ssp. bulgaricus LMG 6901, and 50 μL of
each neutralised supernatant was added to the wells. The plates
were incubated anaerobically at 37◦C overnight and observed for
zones of inhibition around the well (Ryan et al. 1996). Strains
showing zones of inhibition were selected for further study.
16S rRNA sequencing
Genomic DNA was extracted from the antimicrobial-producing
strains (grown overnight in 10 mL BHI broth at 37◦C) using a
Sigma-Aldrich DNA purification kit as described by the man-
ufacturer (Sigma-Aldrich Ireland Limited, Vale Road, Arklow,
Co. Wicklow, Ireland). For 16S rRNA sequencing, universal
primers Uni F 5′-AGAGTTTGATCCTGGCTCAGG-3′ and Uni R
5′-ACGGCAACCTTGTTACGAGT-3′ were used for PCR reactions
(run conditions: initial denaturation: 94◦C × 5 min, cycling
conditions: 30 cycles of 94◦C × 40 s, 55◦C × 30 s, 72◦C × 1
min, final extension: 72◦C × 10 min) to initially identify the
D
ow
nloaded from
 https://academ
ic.oup.com
/fem
sec/article-abstract/95/2/fiy241/5259109 by U
niversity C
ollege C
ork user on 13 June 2019
O’Sullivan et al. 3
Table 1. Growth conditions of the indicator strains used in this study.
Growth conditions
Species Strain
Temp
(◦C) Atmosphere Growth media
Bifidobacterium longum subsp. infantis ATCC 15697 37 Anaerobic∗ mMRS
Bifidobacterium longum subsp. longum DSM 20097 37 Anaerobic mMRS
Corynebacterium xerosis DPC 5629 37 Aerobic BHI
Corynebacterium variablis NCIMB 702097 30 Aerobic BHI
Cutibacterium acnes LMG 16711 37 Anaerobic mRCM & RCA
Enterococcus faecalis ATCC 19433 37 Anaerobic MRS
Fusobacterium varium DSM 19868 37 Anaerobic BHI
Lactobacillus delbrueckii subsp.
bulgaricus
LMG 6901 37 Anaerobic MRS
Lactobacillus fermentum APC 2582 37 Anaerobic MRS
Lactobacillus rhamnosus APC 3483 37 Anaerobic MRS
Listeria innocua DPC 3572 37 Aerobic BHI
Listeria monocytogenes DPC 5788 37 Aerobic BHI
Listeria monocytogenes DPC 6893 37 Aerobic BHI
Listeria monocytogenes NCTC 5348 37 Aerobic BHI
Pseudomonas aeruginosa NCIMB 8295 37 Aerobic BHI
Pseudomonas aeruginosa APC 2064 37 Aerobic BHI
Pseudomonas fluorescens DPC 6056 30 Aerobic BHI
Pseudomonas putita ATCC 17522 37 Aerobic BHI
MRSA DPC 5645 37 Aerobic BHI
Staphylococcus aureus ATCC 25923 37 Aerobic BHI
Staphylococcus aureus DPC 7016 37 Aerobic BHI
Staphylococcus capitis APC 2923 37 Aerobic BHI
Staphylococcus epidermidis DPC 5990 37 Aerobic BHI
Staphylococcus simulans APC 3482 37 Aerobic BHI
Streptococcus agalactiae ATCC 13813, APC 1055 37 Aerobic BHI
Streptococcus bovis DPC 6491 37 Aerobic GM17
Streptococcus dysgalactiae APC 3484 37 Aerobic BHI
Streptococcus uberis DPC 5344 37 Aerobic BHI
mMRS = modified MRS, mRCM = modified Reinforced Clostridial Media (made following ATCC Medium:2107 Modified Reinforced Clostridial agar/broth (pre-reduced)
protocol), RCA = Reinforced Clostridium agar.
∗= Anaerobic conditions, where required, were achieved through the use of anaerobic jars and Anaerocult A gas packs (Merck, Darmstadt, Germany).
ATCC = American Type Culture Collection, APC = APC Microbiome Ireland Culture Collection, DPC = Teagasc Culture Collection, WSLC = Weihenstephan Listeria
Collection, LMG = Laboratorium voor Microbiologie, Universteit Gent, Belgium.
Figure 1. (A) Overlay of an original plate containing dilution of a toe swab with L. delbrueckii ssp. bulgaricus LMG 6901. (B) Spot assay of 10 μL of inoculum from colonies
of varying morphologies isolated from swab dilution plates, overlaid with L. delbrueckii ssp. bulgaricus LMG 6901. (C) Well diffusion assay of antimicrobial-producing
skin isolates in agar seeded with L. delbrueckii ssp. bulgaricus LMG 6901 to confirm that the positive result in spot assay was due to antimicrobial substance secreted
into CFS.
antimicrobial-producing strains. To confirm species, degener-
ate primers targeting the dnaJ gene (Shah et al. 2007) forward
primer, 5′-GCCAAAAGAGACTATTATGA-3′, and reverse primer,
5′-ATTGYTTACCYGTTTGTGTACC-3′, were used for the PCR reac-
tions, following conditions described by Shah et al. (2007). Quan-
tification of the extracted DNA and PCR products was conducted
using a Qubit 2.0 fluorometer (Thermo Fisher Scientific, 168
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Third Avenue Waltham, MA USA 02451). Sequencing was con-
ducted by Genewiz (Hope End, Takeley, Essex, CM22 6TA, United
Kingdom) and analyses of the sequencing data were performed
utilising Lasergene 8 software (DNAStar Inc., Madison,WI). Basic
local alignment search tool (BLAST) on the National Centre for
Biotechnology Information (NCBI) server (http://www.ncbi.nlm
.nih.gov) was used to compare the sequencing data of the iso-
lates to existing genomic data.
Heat stability and protease sensitivity
To establish the heat stability of bacteriocins produced, CFSwere
incubated for 10 min at a range of temperatures, 37, 60, 70, 80,
90, 100◦C, and for 15 min at 121◦C before performing a WDA
in 1.5% MRS agar seeded with 0.25% L. delbrueckii ssp. bulgari-
cus LMG 6901 as previously described; see Fig. S2A (Supporting
Information).
To investigate whether the antimicrobials produced were
proteinaceous in nature, the CFS of all antimicrobial-producing
isolates were incubated with Proteinase K (Sigma) to a final con-
centration of 20 mg/mL at 37◦C for 1 hr and tested for antimi-
crobial activity by a WDA using L. delbrueckii ssp. bulgaricus LMG
6901 as the target organism as described above. The correspond-
ing CFS, mixed with an equivalent volume of water, was used as
a control; see Fig. S2B and S2C (Supporting Information).
Cross-immunity
To determine the relatedness of the bacteriocins produced by
the strains, cross-immunity assays were performed as follows:
CFS of all producing strains were tested against each other by
conducting WDA assays as previously described using each pro-
ducing strain as a producer and also as a target strain. Each
producing strain was inoculated individually (at 0.25%) into
BHI agar, which was allowed to solidify and 50 μL of the pH-
neutralised CFS of each strain was added to wells of all plates;
see Fig. 2.
Spectrum of inhibition
A spectrum of inhibition was completed on pH-adjusted CFS of
all antimicrobial-producing isolates using 28 indicator strains by
aWDA as described previously. All indicator strains were diluted
to the same optical density, (OD600 nm 0.8), using a Biochrom
Libra S2 Colorimeter (Biochrom Ltd., Cambourne Business Park,
Cambridge, United Kingdom) before seeding the agar. Indicator
strains employed to detect antimicrobial activity and their opti-
mal growth conditions are listed in Table 1. Zone size was mea-
sured as follows: area of zone πr2 − area of well πr2 in millime-
tres.
Pulsed Field Gel Electrophoresis
All isolates identified as Staphylococcus species were fin-
gerprinted using Pulsed Field Gel Electrophoresis (PFGE) as
described by Bannerman et al. (1995) with minor modifications.
Cultures were inoculated at 0.02% and grown in a shaking incu-
bator overnight in 5 mL BHI broth at 37◦C. The overnight cul-
ture (0.7 mL) was centrifuged for 2 min at 4500 × g in an Eppen-
dorf centrifuge. The supernatant was discarded, and the cell
pellets were washed in 1 mL of sterile TE buffer (0.1 M Tris Cl,
0.15 M NaCl, 0.1 M EDTA, pH7.5) and recentrifuged. Washed cells
were resuspended in 0.3 mL sterile EC buffer (6 mM Tris-HCl, 1
M NaCl, 0.1 M EDTA, 1% Sarkosyl). A solution of lysostaphin (1
mg/mL) was prepared in 20 mM sodium acetate (pH 4.5) and 2
μL was added to the cell suspension and then vortexed. A 2%
Sea Plaque agarose (Bio-Rad Laboratories Ltd., Watford, Hert-
fordshire, United Kingdom) solution was prepared in EC buffer
and 300 μL added to 300 μL lysostaphin-cell suspension was
mixed gently to avoid the formation of bubbles and then quickly
pipetted into PFGE plug molds. The agar plugs were allowed to
solidify at room temperature for 10 min. When solidified, the
plugs were incubated in 3 mL EC buffer overnight at 37◦C. After
overnight incubation, the EC buffer was removed and replaced
with 3 mL TE buffer (10 mM Tris Cl, 1 mM EDTA) and incubated
for 1 hr at 55◦C without shaking. Prior to electrophoresis, the
plugs were cut into small slices of 2 × 5 mm and transferred
into Eppendorf tubes containing 125 μL of 20U Sma1 restriction
enzyme (New England Biolabs, 75–77 Knowl Piece, Wilbury Way,
Hitchin, Herts, United Kingdom) in buffer. Plugs were incubated
overnight with shaking (300 rpm) at 25◦C. Following digestion,
trimmed slices of plug were loaded onto the PFGE comb, fixed
with 1% PFGE-grade agarose (Bio-Rad Laboratories) in 0.5X Tris-
borate EDTA (TBE) buffer. Lambda PFGE marker (New England
Biolabs) was loaded onto the gel as described above and used
as a reference ladder. The gel was run in 0.5X TBE buffer using
a CHEF-DR II R©PFGE apparatus using the following gel running
parameters: initial pulse 5 s, final pulse 40 s, voltage 200 V or 6
V/cm for 20 hr at 12–14◦C. The gelwas stained for 2 hrwith ethid-
ium bromide (0.5 μg/mL), destained for 1 hr in distilled water
and photographed using a GelDoc-It Imager (Ultra-Violet Prod-
ucts Ltd., Cambridge, United Kingdom).
Activity units
For the 13 different antimicrobial-producing strains identified
from PFGE, bacteriocin activity units (AU) were calculated as
described by Nilsen, Nes and Holo (2002) based on the WDA.
Briefly, 50 μL of CFS was diluted twofold and dilutions were
dispensed into wells of plates seeded with indicators listed in
Table 4. AU were calculated by multiplying the reciprocal of the
lowest dilution of the CFS, which produced zones of inhibition
by 20 in order to obtain AU/mL; see Table 4. This assay was per-
formed in duplicate.
MALDI TOF mass spectrometry
Colonies from the 13 antimicrobial-producing skin isolates were
mixed with 50 μL propan-2-ol 0.1% TFA, vortexed three times
and centrifuged at 16 000 × g for 30 s. MALDI TOF mass spec-
trometrywas performed on the CFS using an Axima TOF2 MALDI
TOF mass spectrometer (Shimadzu Biotech, Manchester, UK).
An aliquot (0.5 μL) of matrix solution (α-cyano 4-hydroxy cin-
namic acid, 10 mg mL−1 in acetonitrile-0.1% (v/v) trifluoroacetic
acid) was deposited onto the target and left for 10 s before being
removed. The residual solutionwas allowed to air-dry and 0.5μL
of the sample solution was deposited onto the pre-coated sam-
ple spot; 0.5 μL of matrix solution was added to the deposited
sample and allowed to air-dry. The sample was then analysed
in the positive-ion linear mode and peptide masses were com-
pared to the bacteriocin database ‘Bactibase’ to identify putative
bacteriocins.
RESULTS AND DISCUSSION
The human skin microbiome is home to trillions of bacteria but
is predominately colonised bymembers of the genus Staphylococ-
cus (Otto 2010). The skin is the defensive barrier that separates
our internal organs from the external world. It acts as a first line
of defence against pathogens, and the layers of skin help prevent
harmful substances from accessing the body (Sanford and Gallo
2013; Zeeuwen et al. 2013). Significant therapeutic potential has
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Figure 2. Cross-immunity assays using CFS from all the antimicrobial-producing strains tested against themselves and each other, with the list of antimicrobial-
producing isolates down the left-hand side and the indicator strains across the top of the table. The diagonal green line reveals that the antimicrobial producer is
immune to its own antimicrobial, as expected. The red box represents inhibition of the indicator strain indicating that these strains might be different or sensitive
to each other. (orange) = small/ medium hazy zones. (yellow) = very small zones but sensitive. White boxes represent no inhibition, revealing target strains not
inhibited by the producing strain, indicating they are immune (related) to the bacteriocins produced by other producers. ∗ = initially sensitive but bactostatic activity
observed.
been identified for the staphylococcal genus, including the pro-
duction of class 1a lantibiotics such as epidermin, nukacin, gal-
lidermin and aureocin (Schnell et al., 1989, 1992; Sashihara et al.
2000; Netz et al. 2002), as well as a novel antibiotic lugdenin (Zip-
perer et al. 2016). Consequently, a culture-based approach was
adopted in this study to isolate antimicrobial-producing bacte-
ria with a particular focus on those that exhibit inhibitory activ-
ity against bacteria involved in the pathogenesis of skin infec-
tions. These includeMRSA, S. epidermidis, Cutibacterium acnes and
a number of mastitic pathogens, such as Streptococcus uberis,
Streptococcus bovis, Streptococcus agalactiae, Streptococcus dysgalac-
tiae and S. aureus.
Detection and isolation of antimicrobial-producing skin
isolates
Twenty volunteers of mixed age, gender and race were recruited
to provide swabs from seven body locations. The body sites were
chosen based on the varied bacterial compositions of differ-
ent skin areas (Grice and Segre 2011). Superficial swabs were
employed in this study because the swabbing method was less
invasive and was reported to yield a largely similar microbiota
profile to that associated with skin scraping of epidermis or
punch biopsy of the full thickness of epidermis and dermiswhen
next-generation sequencing methods were used (Grice et al.
2008). Over 90,000 colonies were initially screened for antimi-
crobial activity; thesewere isolated from 7 sites from the 20 indi-
viduals (140 sites) using the agar overlay technique on the orig-
inal isolation plates. Samples were serially diluted and spread-
plated onto the surface of BHI andMSA agar plates and all plates
that contained visible growth were counted as potential antimi-
crobial producers and overlaid with L. delbrueckii ssp. bulgaricus
or MRSA/L. innocua, respectively. At this stage of the study, the
genetic relationship between the colonies was not determined.
Spot bioassays on selected individual colonies and original plate
overlays identified 101 possible antimicrobial-producing isolates
(see the supplementary information for more details). To con-
firm that an antimicrobial substance was secreted into the
growthmedium, neutralised CFSwas tested against L. delbrueckii
ssp. bulgaricus LMG 6901 by WDA and this reduced the number
of possible bacteriocin producers to 25, giving an observed fre-
quency of 0.03% from the 90000 colonies screened in this study.
Due to small zone sizes, four of the antimicrobial producerswere
discarded. Lactobacillus delbrueckii ssp. bulgaricus LMG 6901 was
selected as the primary indicator for all assays because of its
insensitivity to acids, thus reducing the frequency of false posi-
tives (Casey et al. 2004). While it is now accepted that many bac-
teria in natural ecosystems have the genetic potential to pro-
duce bacteriocin-like inhibitors, their detection in vitro is largely
dependent on the screening methods undertaken. The low fre-
quency observed in this study may contribute to the fact that
only L. delbrueckii ssp. bulgaricus was used as the primary indi-
cator bacterium.
Identification of antimicrobial-producing skin isolates
16S rRNA sequencing of the 25 antimicrobial-producing iso-
lates revealed four Bacillus species—Bacillus licheniformis (2), Bacil-
lus endophyticus and Bacillus safensis—but the remainder were
coagulase-negative Staphylococcus species. However, additional
analysis by amplification of the dnaJ gene was required to fur-
ther differentiate the Staphylococcus species. Five Staphylococcus
species were identified, including S. capitis (9), S. hominis (4), S.
epidermidis (1), S. simulans (1) and S. warneri (6) (Table 2). Staphylo-
coccus capitis, a frequent coloniser of human skin, was the most
prevalent species isolated (43%) followed by S. warneri (29%),
which has been reported to be a less-frequent skin coloniser
(Otto 2010) ). Twelve strains (∼50%) of antimicrobial-producing
staphylococci were isolated from the toe web-space body area.
The four antimicrobials which were omitted from the study, as
they were considered poor producers, were Bacillus species.
Characterisation of antimicrobial-producing skin
isolates
A characteristic of bacteriocins is that they are relatively heat
stable and are susceptible to degradation by proteolytic enzymes
(Jack, Tagg and Ray 1995). Antimicrobial activity in the CFS from
all strains was eliminated following Proteinase K treatment,
indicating that the antimicrobials were proteinaceous in nature
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Table 2. Identification of antimicrobial-producing strains isolated from skin.
Strain Identity Strain number Subject no. Body area PFGE lane no.
Staphylococcus hominis APC 2925 SM019 toe web-space 1$
Staphylococcus hominis APC 2924 SM012 toe web-space 2
Staphylococcus hominis APC 2939 SM019 gluteal crease 3$
Staphylococcus hominis APC 3365 SM020 gluteal crease 4
Staphylococcus warneri APC 2942 SM009 axillary vault 5∗
Staphylococcus warneri APC 2922 SM001 toe web-space 6
Staphylococcus warneri APC 2937 SM006 gluteal crease 7∗
Staphylococcus warneri APC 2947 SM007 toe web-space 8
Staphylococcus warneri APC 2940 SM007 gluteal crease 9∗
Staphylococcus warneri APC 2930 SM015 toe web-space 10
Staphylococcus epidermidis APC 3477 SM015 toe web-space 11
Staphylococcus simulans APC 2926 SM002 toe web-space 12
Staphylococcus capitis APC 2934 SM003 inguinal crease 13
Staphylococcus capitis APC 2918 SM001 alar crease 14
Staphylococcus capitis APC 2923 SM007 toe web-space 15
Staphylococcus capitis APC 2941 SM010 umbilicus 16
Staphylococcus capitis APC 3480 SM009 umbilicus 17
Staphylococcus capitis APC 2946 SM008 toe web-space 18
Staphylococcus capitis APC 2932 SM008 toe web-space 19
Staphylococcus capitis APC 2927 SM015 toe web-space 20π
Staphylococcus capitis APC 3481 SM015 toe web-space 21π
$, ∗, , πThese symbols reflect identical PFGE patterns from Figure 3.
(Fig. S2, Supporting Information). In addition, all antimicrobials
were stable up to 100◦C for 10min and showed only a 50% reduc-
tion in activity after autoclaving at 121◦C for 15min (Fig. S2, Sup-
porting Information).
One of the features of bacteriocin production is that the
genome of producers must harbour immunity gene(s), which
protect producers from the antimicrobial effects of the bacte-
riocin they produce (Cotter, Hill and Ross 2005; Yang et al. 2014).
Cross-immunity assays were performed to determine whether
the producing strains were sensitive to the antimicrobial activ-
ity of the other producers (Fig. 2). To determine the genetic relat-
edness of the 21 staphylococci isolated, the strains were fin-
gerprinted using PFGE and similarities were categorised on the
basis of the procedure described by Tenover et al. (1995). Strains
of the same species are closely related, in some cases only differ-
ing from each other by a single DNA band, for example S. hominis
strains APC 2925, APC 2924 and S. capitis strains APC 2934 and
APC 2918 (Fig. 3). However, the PFGE analysis revealed 13 genet-
ically different antimicrobial-producing staphylococci—three S.
hominis, four S. warneri, one S. epidermidis, one S. simulans and
four S. capitis.
Combining data from cross-immunity assays and PFGE anal-
ysis revealed that antimicrobials produced by skin isolates of
the same species and of the same or similar pulsotype were
immune to each other, suggesting they are producing the same
bacteriocin and are possibly the same strain. For example, two
S. hominis strains APC 2925 and APC 2939, isolated from differ-
ent body areas (toe web-space and gluteal crease) of the same
subject, yielded the same pulsotype (lanes 1 and 3 on PFGE gel)
and had the same immunity pattern as another S. hominis strain,
APC 2924, from a different subject whose pulsotype differed by
just one Sma1 digestion DNA band (lane 2 on PFGE gel). This was
also the case for two S. capitis strains from two different subjects
(APC 2934 and APC 2918, lanes 13 and 14 of PFGE gel). This shows
that some different strains that are closely related can produce
the same bacteriocin.
PFGE profiles demonstrated that the same pulsotype can be
shared across a number of individuals, with the same S. capi-
tis pulsotype isolated from four different subjects (Fig. 3, lanes
15–19) and three subjects sharing the same S. warneri pulsotype:
APC 2942, APC 2937 and APC 2940 (Fig. 3, lanes 5, 7 and 9). Inter-
estingly, we also showed that the same subject can carry more
than one strain of the same species; S. warneriAPC 2947 and APC
2940 were isolated from the subject 7. These strains were iso-
lated from different locations on the body and exhibited differ-
ent pulsotypes—(Fig. 3, lanes 8 and 9). S. warneri APC 2947 had
a very different pulsotype to other S. warneri strains isolated in
this study, and while it was immune to the bacteriocin produced
by others of the same species, it had a different immunity pat-
tern in that it was inhibited by S. capitis skin isolates unlike other
S. warneri (Figs 2 and 3, lane 8).
Bacteriocins such as thuricin CD and nisin have either a nar-
row or broad spectrum of activity, respectively (Rea et al. 2010;
Shin et al. 2016), and both of these characteristics may be ben-
eficial to the producing strain depending on the niche inhab-
ited by the bacterium. In a crowded environment like the skin,
bacteriocin production might help producing strains establish
themselves in a particular skin environment. For example, the
production of narrow spectrum bacteriocins may confer a com-
petitive advantage to strains, allowing them to inhibit closely
related species that would be competing for similar nutrients
on the skin (Dobson et al. 2012). Table 3 shows the spectrum of
inhibition of the bacteriocins produced against a panel of bac-
teria including skin pathogens such as C. acnes, S. epidermidis,
Corynebacterium xerosis (C. xerosis) and MRSA. The majority of S.
warneri exhibited the broadest spectrum of activity, inhibiting
nine of the indicator strains,while the inhibitory activity of three
strains (APC 2930, APC 3477 and APC 2926) was shown to exhibit
a narrow inhibition spectrum—inhibiting only the primary indi-
cator L. delbrueckii ssp. bulgaricus LMG 6901.
While themajority of our commensal or resident skinmicro-
biota are beneficial to skin health, occasionally themicrobes that
inhabit our skin can develop into opportunistic pathogens, for
D
ow
nloaded from
 https://academ
ic.oup.com
/fem
sec/article-abstract/95/2/fiy241/5259109 by U
niversity C
ollege C
ork user on 13 June 2019
O’Sullivan et al. 7
Ta
b
le
3.
Sp
ec
tr
u
m
of
in
h
ib
it
io
n
of
ba
ct
er
io
ci
n
-p
ro
d
u
ci
n
g
sk
in
is
ol
at
es
ag
ai
n
st
in
d
ic
at
or
st
ra
in
s
su
bj
ec
te
d
to
w
el
ld
if
fu
si
on
as
sa
ys
.+
<
50
m
m
2
;+
+5
0–
15
0m
m
2
;+
++
15
0–
24
9m
m
2
;+
++
+
25
0–
34
9m
m
2
;
35
0–
44
9m
m
2
;+
++
++
+>
45
0
(c
al
cu
la
te
d
as
ar
ea
of
zo
n
e
π
r2
–
ar
ea
of
w
el
lπ
r2
in
m
il
li
m
et
re
s)
.
S.
ho
m
in
is
S.
w
ar
ne
ri
S.
ep
id
er
m
id
is
S.
si
m
u
la
ns
S.
ca
pi
ti
s
Pr
od
u
ce
r
st
ra
in
s
29
25
29
24
29
39
33
65
29
42
29
22
29
37
29
47
29
40
29
30
34
77
29
26
29
34
29
18
29
23
29
41
34
80
29
46
29
32
29
27
34
81
C
or
yn
eb
ac
te
ri
a
xe
ro
si
s
D
PC
56
29
++
++
++
−
++
+
++
+
++
+
++
+
++
+
−
−
−
−
−
−
−
−
−
−
−
−
C
u
ti
ba
ct
er
iu
m
ac
ne
s
LM
G
16
71
1
−
−
−
++
−
−
−
−
−
−
−
−
++
++
++
++
++
++
++
−
−
La
ct
ob
ac
ill
u
s
bu
lg
ar
ic
u
s
LM
G
69
01
++
++
++
++
++
++
++
++
++
++
++
++
++
+
++
++
++
++
++
++
++
+
++
++
+
+
++
++
++
++
+
++
++
++
++
++
++
++
++
++
++
++
++
++
++
+
++
++
+
La
ct
ob
ac
ill
u
s
fe
m
en
tu
m
A
PC
25
82
++
++
++
+
++
+
++
++
++
++
−
−
−
++
++
+
+
+
+
+
+
+
Li
st
er
ia
m
on
oc
yt
og
en
es
D
PC
68
93
++
++
++
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
M
R
SA
D
PC
56
45
−
−
−
−
−
−
−
−
−
−
−
−
++
++
−
−
−
−
−
−
−
St
ap
hy
lo
co
cc
u
s
au
re
u
s
A
T
C
C
25
92
3
−
−
−
−
−
−
−
−
−
−
−
−
++
++
−
−
−
−
−
−
−
St
ap
hy
lo
co
cc
u
s
au
re
u
s
D
PC
70
16
−
−
−
++
++
++
++
++
−
−
−
−
++
++
−
−
−
−
−
−
−
St
ap
hy
lo
co
cc
u
s
ep
id
em
id
is
D
PC
59
90
−
−
−
−
−
−
−
−
−
−
−
−
++
++
+
++
++
+
−
−
−
−
−
−
−
St
ap
hy
lo
co
cc
u
s
si
m
u
la
ns
A
PC
34
82
−
−
−
−
−
−
−
−
−
−
−
−
−
−
++
++
++
++
++
++
++
St
re
pt
oc
oc
cu
s
ag
al
ac
ti
ae
A
PC
10
55
++
++
++
−
++
+
++
+
++
+
++
+
++
+
−
−
−
−
+
+
+
+
+
−
−
St
re
pt
oc
oc
cu
s
ag
al
ac
ti
ae
A
T
C
C
13
81
3
++
++
++
++
++
+
++
+
++
+
++
+
++
+
−
−
−
−
−
−
−
−
−
−
−
−
St
re
pt
oc
oc
cu
s
bo
vi
s
D
PC
64
91
++
++
++
+
++
++
++
++
++
−
−
−
−
−
++
+
++
+
++
+
++
+
++
+
−
−
St
re
pt
oc
oc
cu
s
dy
sg
al
ac
ti
ae
A
PC
34
84
++
++
++
++
++
++
++
++
++
−
−
−
−
−
−
−
−
−
−
−
−
St
re
pt
oc
oc
cu
s
ti
be
ri
s
D
PC
53
44
−
−
−
−
++
+
++
+
++
+
++
+
++
−
−
−
−
++
+
++
+
++
+
++
+
++
+
++
++
O
th
er
in
d
ic
at
or
st
ra
in
s
th
at
th
e
sk
in
an
ti
m
ic
ro
bi
al
p
ro
d
u
ce
rs
w
er
e
te
st
ed
ag
ai
n
st
ca
n
be
se
en
on
Ta
bl
e
1.
D
ow
nloaded from
 https://academ
ic.oup.com
/fem
sec/article-abstract/95/2/fiy241/5259109 by U
niversity C
ollege C
ork user on 13 June 2019
8 FEMS Microbiology Ecology 2019, Vol. 95, No. 2
Figure 3. PFGE macrodigestion patterns of staphylococcal skin isolates following genomic digestion with Sma1. Lanes 1–4 = Staphylococcus hominis: APC 2925, 2924,
2939 and 3365; lanes 5–10 = Staphylococcus warneri: APC 2942, 2922, 2937, 2947, 2940 and 2930; lane 11 = Staphylococcus epidermidis: APC 3477; lane 12 = Staphylococcus
simulans APC 2926; lanes 13–21 = Staphylococcus capitis APC 2934, 2918, 2923, 2941, 3480, 2946, 2932, 2927 and 3481. Lanes 4, 14 and 21 were taken from other PFGE gels
with the same lambda marker (M) and input into this gel. epi = epidermidis; sim = simulans. Artefact in lane 3 below the first band is not a Sma1 DNA band.
example S. lugdunensis and S. capitis (Bo¨cher et al. 2009; Cameron
et al. 2015). Even the most abundant species of Staphylococcus on
human skin, S. epidermidis, can become pathogenic if the condi-
tions are suitable (Cogen, Nizet and Gallo 2008). Disruptions to
the microbial composition of the skin are responsible for skin
conditions such as psoriasis, atopic dermatitis, impetigo and
acne, and sometimes these imbalances can also prevent healing
of chronic wounds (Grice 2014). Two S. capitis strains (APC 2934
and APC 2918) isolated in this study exhibited inhibitory activity
of 160 AU/mL against S. epidermidis (DPC 5990) (Tables 3 and 4).
S. aureus in particular is known for developing antibiotic
resistance (Chambers and Deleo 2010). MRSA was first identi-
fied in 1960 and since then has become one of the most preva-
lent antibiotic resistant pathogens worldwide and is charac-
terised by swollen red lesions containing pus following infection
of skin wounds; it also causes many other diseases, including
pneumatic diseases that can result in mortality in the elderly.
A study investigating incidence of MRSA in S. aureus isolates in
the Prince of Songkhla Hospital, Thailand found that 60.9% of
the S. aureus isolates were methicillin resistant (Indrawattana
et al. 2013), while a study on skin and soft tissue infections car-
ried out in medical centres in Europe revealed that the most
prevalent pathogen was MRSA (22.5%) (Johnson 2011). MRSA is
first treated with glycopeptide antibiotics such as vancomycin,
(Santajit and Indrawattana 2016). However, the development
of novel antimicrobial therapies for methicillin-resistant and
vancomycin-resistant S. aureus are included in the second high-
est priority group in a list of priority pathogens published by
the WHO in a recent report describing antimicrobial resistance
as a ‘global emergency’ (http://www.who.int/antimicrobial-resi
stance/en/). Alternative interventions to alleviate the problems
posed by MRSA and other antimicrobial resistant pathogens are
urgently required. S. capitis strains APC 2934 and APC 2918 with
very similar pulsotypes (Fig. 3, lanes 13 and 14) were isolated in
this study from two different subjects, fromdifferent body areas,
namely the inguinal crease and alar crease, andwere immune to
each other’s antimicrobial activity (Fig. 2). These strains exhib-
ited inhibitory activities, 80 AU/mL and 40 AU/mL respectively,
against a strain of the skin pathogen MRSA (DPC 5645) (Tables 3
and 4).
Many adolescents and adults will experience the effects of
acne vulgaricus at some point in their lives (Webster 2002).
Patients suffering from mild acne are often prescribed top-
ical antibiotics or antiseptics at the beginning of treatment,
such as clindamycin, erythromycin, benzoyl peroxide, topi-
cal retinoid or a combination of these products. However, if
these are ineffective, or if the acne is classified as moderate
to severe, then patients are often prescribed systemic treat-
ments including oral antibiotics including tetracyclines, ery-
thromycin, trimethoprim–sulfamethoxazole hormone therapy
and retinoid-isotreretinoin, often for long periods (Rathi 2011).
According to TIME Health, acne patients stay on antibiotics for
four times the recommended time period. Eight skin isolates in
this study displayed inhibitory activity of 40 AU/mL against C.
acnes, which is a leading cause of acne vulgaricus (see Tables 3
and 4). Seven of these isolateswere S. capitis; however, therewere
three distinct pulsotypes. S. hominis APC 3365 was also active
against C. acnes.
C. xerosis is a Gram-positive aerobic bacterium, and a com-
mensal of the human skin. C. xerosis can cause bacteremia,
skin infections, endocarditis and pneumonia in immune-
compromised patients (Pessanha et al. 2003). Three S. homi-
nis and five S. warneri demonstrated inhibitory activities of 40
AU/mL and 80 AU/mL against C. xerosis (Tables 3 and 4), and
against other Corynebacterium species (results not shown). PFGE
analysis revealed five distinct pulsotypes (two S. hominis and
three S. warneri strains (Fig. 3)). In addition to highlighting the
therapeutic potential of coagulase-negative staphylococci on
human skin by inhibiting skin pathogens, we also observed the
ability of skin commensals to inhibit other pathogens such as
Listeria monocytogenes (Table 3, APC 2924, APC 2925, APC 2939-
2 distinct strains from PFGE, Fig. 3) and Streptococcus species
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Table 4. Activity units per mL (AU/mL) from well diffusion assays of the 13 different bacteriocin-producing skin isolates against indicator
strains. (S. hominis APC 2925, 2924, 3365; S. warneri APC 2922, 2937, 2947, 2930; S. epidermidis APC 3477; S. simulans APC 2926; S. capitis APC 2934,
2918, 2923, 2927).
Bacteriocin producing strains
Indicator strains 2925 2924 3365 2922 2937 2947 2930 3477 2926 2934 2918 2923 2927
Corynebacterium xerosis DPC 5629 40 40 – 80 80 80 – – – – – – –
Cutibacterium acnes LMG 16711 – – 40 – – – – – – 40 40 40 –
Lactobacillus bulgaricus LMG 6901 80 80 320 640 640 640 160 320 40 80 80 1280 640
Lactobacillus fermentum APC 2582 40 40 20 80 80 80 – – – 20 20 40 20
Listeria monocytogenes DPC 6893 40 40 – – – – – – – – – – –
MRSA DPC 5645 – – – – – – – – – 80 40 – –
Staphylococcus aureus ATCC
25923
– – – – – – – – – 40 40 – –
Staphylococcus aureus DPC 7016 – – – 80 20 40 – – – 40 40 – –
Staphylococcus epidermidis DPC 5990 – – – – – – – – – 160 160 – –
Staphylococcus simulans APC 3482 – – – – – – – – – – – 40 40
Streptococcus agalactiae APC 1055 20 20 20 320 80 80 – – – – – 20 –
Streptococcus agalactiae ATCC
13813
20 20 – 80 80 80 – – – – – – –
Streptococcus bovis DPC 6491 40 40 20 40 40 80 – – – – – 320 –
Streptococcus dysgalactiae APC 3484 40 40 – 80 40 40 – – – – – – –
Streptococcus uberis DPC 5344 – – – 80 40 40 – – – – – 40 20
involved in bovine mastitis, such as St. uberis, St. agalactiae and
St. dysgalactiae (Table 3). While traditionally S. aureus was the
most common cause of mastitis in dairy cows, more recently
St. uberis has been shown to be increasingly associated with
infection (Kromker, et al. 2014). In this study, three Staphylococ-
cus species, S. hominis, S. warneri and S. capitis inhibited a range
of Streptococcus species (St. uberis, St. bovis, St. agalactiae and
St. dysgalactiae), which have been implicated in bovine masti-
tis (Table 3) with AU ranging from 20 to 320 AU/mL (Table 4).
Streptococcus uberis is of particular interest as it has been increas-
ingly shown to be one of the causative agents of bovine mastitis
in the UK. This shows that the antimicrobial-producing human
skin isolates may also have applications in veterinary medicine
for the treatment of mastitis, given their ability to inhibit both
Staphylococcus and Streptococcus species, and could aid in the
search for non-antibiotic solutions for mastitis treatment to
reduce antibiotics in the food chain. Mastitis in humans is also
a major health issue (Michie, Lockie and Lynn 2003). Staphylococ-
cus epidermidis and streptococci are among the most prevalent
causative agents of this infection, found in 87.6% and 68.6% of
mastitic human breast milk samples, respectively (Marı´n et al.
2017). Bacteriocin producers from human skin, identified in this
study, exhibited inhibitory activity against Staphylococcal and
Streptococcal species, thus highlighting their potential as live bio-
therapeutics for the treatment of human mastitis.
Colonymass spectrometry can be used to identify antimicro-
bial peptides if they can bematched to known peptidemasses in
the Bactibase database. However, in this case the peptidemasses
detected did not match any known bacteriocins, suggesting
these isolates are potentially producing novel bacteriocins. The
Maldi-TOFMS profiles of the 13 antimicrobial-producing staphy-
lococci are shown in Fig. S3, Supporting Information.
CONCLUSION
There is a need to identify new antimicrobial strains with the
potential to outcompete pathogens in the skin environment.
The skin is a protective defence, shielding us from the external
environment (Yamasaki and Gallo 2008). This study has high-
lighted that the skin microbiota is home to many bacteriocin-
producing strains, which may indicate that the skin microbiota
is an important tool in our fight against antimicrobial resistance.
Indeed, this screening has resulted in the isolation of a set of
13 novel bacteriocin-producing human skin isolates with poten-
tial to restore imbalances of skin microbiota as well as to inhibit
skin pathogens such as MRSA and C. acnes. More importantly,
these strains may prove useful as probiotics for topical skin
applications to provide colonization resistance by replacement
of skin pathogens and particularly MRSA. Further characterisa-
tion studies will be carried out on these bacteriocin-producing
skin isolates.
SUPPLEMENTARY DATA
Supplementary data are available at FEMSEC online.
ACKNOWLEDGEMENTS
JO’S was supported by a studentship from Science Foundation
Ireland (SFI; www.sfi.ie) under Grant Number SFI/12/RC/2273.
FUNDING
This work was supported by a grant from Science Foundation
Ireland (SFI; www.sfi.ie) (grant Number SFI/12/RC/2273).
Conflicts of interest. None declared.
REFERENCES
Bannerman TL, Hancock GA, Tenover FC et al. Pulsed-field gel
electrophoresis as a replacement for bacteriophage typing of
Staphylococcus aureus. J Clin Microbiol 1995;33:551–5.
Bastos MCF, Ceotto H, Coelho MLV et al. Staphylococcal antimi-
crobial peptides: relevant properties and potential biotech-
nological applications. Curr Pharm Biotechnol 2009;10:38–61.
D
ow
nloaded from
 https://academ
ic.oup.com
/fem
sec/article-abstract/95/2/fiy241/5259109 by U
niversity C
ollege C
ork user on 13 June 2019
10 FEMS Microbiology Ecology 2019, Vol. 95, No. 2
Bo¨cher S, Tønning B, Skov RL et al. Staphylococcus lugdunensis, a
common cause of skin and soft tissue infections in the com-
munity. J Clin Microbiol 2009;47:946–50.
Cameron DR, Jiang JH, Hassan KA et al. Insights on virulence
from the complete genome of Staphylococcus capitis. Front
Microbiol 2015;6:1–12.
Casey PG, Casey GD, Gardiner GE et al. Isolation and characteriza-
tion of anti-Salmonella lactic acid bacteria from the porcine
gastrointestinal tract. Lett Appl Microbiol 2004;39:431–8.
Chambers HF, Deleo FR. Waves of resistance: Staphylococcus
aureus in the antibiotic era. Nat Rev Microbiol 2010;7:629–41.
Cogen AL, Nizet V, Gallo RL. Skin microbiota: a source of disease
or defence? Br J Dermatol 2008;158:442–55.
Cotter PD, Hill C, Ross PR. Bacteriocins: developing innate immu-
nity for food. Nat Rev Microbiol 2005;3:777–88.
Dobson A, Cotter PD, Ross PR et al. Bacteriocin production: a pro-
biotic trait? Appl Environ Microbiol 2012;78:1–6.
Grice E. The skin microbiome: potential for novel diagnostic and
therapeutic approaches to cutaneous disease. Semin Cutan
Med Surg 2014;33:98–103.
Grice EA, Segre JA. The skin microbiome. Nat Rev Microbiol
2011;9:244–53.
Grice EA, Kong HH, Renaud G et al. A diversity profile of the
human skin microbiota. Genome Res 2008;18:1043–50.
Go¨tz F, Perconti S, Popella P et al.‘Epidermin and gallidermin:
Staphylococcal lantibiotics’. Int J Med Microbiol 2014;304:63–
71
Indrawattana N, Sungkhachat O, Sookrung N et al. Staphylococ-
cus aureus clinical isolates: antibiotic susceptibility, molecu-
lar characteristics, and ability to form biofilm. BioMed Res Int
2013;2013:11.
Jack RW, Tagg JR, Ray B. Bacteriocins of gram-positive bacteria.
Am Soc Microbiol 1995;59:171–200.
JohnsonAP.Methicillin-resistant Staphylococcus aureus: the Euro-
pean landscape. J Antimicrob Chemother 2011;66:43–48.
Kromker V, Friederike Reinecke F, Paduch JH et al. Bovine S trep-
tococcus uberis intramammary infections and mastitis. Clin
Microbial 2014;3:4
Landers TF, Hoet A, Wittum TE. Swab type, moistening, and
preenrichment for Staphylococcus aureus on environmental
surfaces. J Clin Microbiol 2010;48:2235–6.
Marı´n M, Arroyo R, Espinosa-Martos I et al. Identification of
emerging human mastitis pathogens by MALDI-TOF and
assessment of their antibiotic resistance patterns. Front
Microbiol 2017;8:1–13.
McAuliffe O, Ross RP, Hill C. Lantibiotics: structure, biosynthesis
and mode of action. FEMS Microbiol Rev 2001;25:285–308.
Michie C, Lockie F, Lynn W. The challenge of mastitis. Arch Dis
Child 2003;88:818–21.
Nakatsuji T, Chen TH, Butcher AM et al. A commensal strain of
Staphylococcus epidermidis protects against skin neoplasia. Sci
Adv 2018;4:eaao4502.
Nakatsuji T, Chen TH, Saisindhu N et al. Antimicrobials from
human skin commensal bacteria protect against Staphylococ-
cus aureus and are deficient in atopic dermatitis. Sci Transl
Med 2017;9:1–22.
Natsuga K. Epidermal barriers. Cold Spring Harbor Perspect Med
2014;4:1–18.
Netz DJ, Pohl R, Beck-Sickinger AG et al. Biochemical char-
acterisation and genetic analysis of aureocin A53, a new,
atypical bacteriocin from Staphylococcus aureus. J Mol Biol
2002;319:745–56.
Nilsen T, Nes IF, Holo H. Enterolysin A, a novel cell wall degrad-
ing bacteriocin secreted from Enterococcus faecalis LMG 2333.
Appl Environ Microbiol 2002;69:2975–84.
Otto M. Staphylococcus epidermidis—the ’accidental’ pathogen.
Nat Rev Microbiol 2009;7:555–67.
Otto M. Staphylococcus colonization of the skin and antimicrobial
peptides. Expert Rev Dermatol 2010;5:183–95.
Pessanha B, Farb A, Lwin T et al. Infectious endocarditis due to
Corynebacterium xerosis. Cardiovasc Pathol 2003;12:98–101.
Rathi SK. Acne vulgaricus treatment : the current scenario. Indian
J Dermatol 2011;56:7–13.
Rea MC, Sit CS, Clayton E et al. Thuricin CD, a posttranslation-
ally modified bacteriocin with a narrow spectrum of activity
against Clostridium difficile. Proc Natl Acad Sci 2010;107:9352–7.
Ryan MP, Rea MC, Hill C et al. An application in cheddar cheese
manufacture for a strain of Lactococcus lactis producing a
novel broad-spectrum bacteriocin, lacticin 3147. Appl Environ
Microbiol 1996;62:612–9.
Sanford JA, Gallo RL. Functions of the skin microbiota in health
and disease. Semin Immunol 2013;25:370–7.
Santajit S, Indrawattana N. Mechanisms of antimicro-
bial resistance in ESKAPE pathogens. BioMed Res Int
2016;2016:2475067.
Sashihara T, Kimura H, Higuchi T et al. Cloning of the gene
encoding a novel lantibiotic, nukacin ISK-1, of Staphylococcus
warneri. J Facult Agricult, Kyushu Univ 2000;45:149–61.
Schauber J, Gallo RL. Antimicrobial peptides and the skin
immune defense system. J Allergy Clin Immunol 2008;122:261–
6.
Schnell N, Engelke G, Augustin J et al. Analysis of genes involved
in the biosynthesis of lantibiotic epidermin. European J
Biochem/FEBS 1992;204:57–68.
Schnell N, Entian KD, Go¨tz F et al. Structural gene isolation and
prepeptide sequence of gallidermin, a new lanthionine con-
taining antibiotic. FEMS Microbiol Lett 1989;49:263–7
Shah MM, Iihara H, Noda M et al. dnaJ gene sequence-based
assay for species identification and phylogenetic grouping in
the genus Staphylococcus. Int J Syst Evol Microbiol 2007;57:25–
30.
Shin JM, Gwak JW, Kamarajan P et al. Biomedical applications of
nisin. J Appl Microbiol 2016;120:1449–65.
Tenover FC, Arbeit RD, Goering RV et al. Interpreting chromo-
somal DNA restriction patterns produced by pulsed- field
gel electrophoresis: criteria for bacterial strain typing. J Clin
Microbiol 1995;33:2233–9.
Webster GF. Clinical review Acne vulgaris. BMJ (Clin Res Ed)
2002;325:475–9.
Yamasaki K, Gallo R. Antimicrobial peptides in human skin dis-
ease. Eur J Dermatol 2008;18:11–21.
Yang S, Lin C, Sung CT et al. Antibacterial activities of bacteri-
ocins: application in foods and pharmaceuticals. Front Micro-
biol 2014;5:1–10.
Zeeuwen PL, Kleerebezem M, Timmerman HM et al.Microbiome
and skin diseases. Curr Opin Allergy Clin Immunol 2013;13:514–
20.
Zipperer A, Konnerth MC, Laux C et al. Human commensals
producing a novel antibiotic impair pathogen colonization.
Nature 2016;535:511–6.
D
ow
nloaded from
 https://academ
ic.oup.com
/fem
sec/article-abstract/95/2/fiy241/5259109 by U
niversity C
ollege C
ork user on 13 June 2019
